Mira Pharmaceuticals signs licensing agreement with Miralogx

Mira Pharmaceuticals announced a partnership with Miralogx, an intellectual property holding company established by Mira‘s founder. Under an exclusive licensing agreement, Mira will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments. This transformative collaboration includes a a $3M line of credit extended by Miralogx to fund the initial development of Ketamir-2.